




RealRate

PHARMACEUTICAL 2017

Biostax Corp.
Rank 286 of 292





PHARMACEUTICAL 2017

Biostax Corp.
Rank 286 of 292



The relative strengths and weaknesses of Biostax Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biostax Corp. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 905% points. The greatest weakness of Biostax Corp. is the variable Assets, Current, reducing the Economic Capital Ratio by 542% points.

The company's Economic Capital Ratio, given in the ranking table, is -766%, being 769% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	74
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,201
Liabilities, Non-Current	0
Other Assets	0.20
Other Compr. Net Income	0
Other Expenses	9,945
Other Liabilities	0
Other Net Income	-5,547
Other Revenues	3.5
Property and Equipment	1.9
Research and Development	444
Selling, General and Administrative Expense	3,887

Output Variable	Value in 1000 USD
Assets	76
Liabilities	9,201
Expenses	14,275
Revenues	3.5
Stockholders Equity	-9,124
Net Income	-19,819
Comprehensive Net Income	-19,819
Economic Capital Ratio	-766%